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Abstract
Purpose—Prostate cancer patients who have undergone androgen deprivation therapy (ADT) 
may experience cognitive impairment, yet there is an unmet need for nonpharmacological 
interventions to address cognitive impairment in this population. This study examines the 
feasibility, acceptability, and preliminary efficacy of a home-based computerized cognitive training 
(CCT) program to treat cancer-related cognitive impairment.
Methods—Sixty men who had received ≥3 months of ADT were screened for at least mild 
cognitive or neurobehavioral impairment and randomized to 8 weeks of CCT or usual care. 
Follow-up assessments occurred immediately post-intervention or equivalent (T2) and 8 weeks 
later (T3). The acceptability of CCT was also assessed.
Results
Feasibility: A priori feasibility thresholds were partially met (i.e., randomization rate >50%, 
retention rate>70% excluding CCT drop-outs, but <70% for intent-to-treat).
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Acceptability: Participants were mostly satisfied with CCT and found it somewhat enjoyable, 
though barriers to uptake existed.
Preliminary efficacy: Linear mixed models indicated significant time by group effects favorable 
to CCT in reaction time (p=.01), but unfavorable to CCT in verbal and visual memory (ps<.05). 
Memory was temporarily suppressed in the CCT group at T2, but normalized by T3. There was no 
effect of CCT on self-reported cognitive functioning, neurobehavioral functioning, nor quality of 
life.
Conclusions—This study provides tentative support for the feasibility and acceptability of CCT 
to treat mild cognitive impairment in ADT patients. CCT had a beneficial effect on reaction time, 
but temporarily suppressed memory. CCT’s benefits may be limited to a narrow area of 
functioning. Larger-scale studies are needed.
Keywords
oncology; hormone therapy; cancer-related cognitive impairment; cognition; computers; 
antiandrogens
BACKGROUND
Androgen deprivation therapy (ADT) is a treatment for prostate-specific antigen recurrence 
following prostate cancer treatment [1, 2] associated with side-effects, including cognitive 
impairment [3, 4]. ADT patients are twice as likely to exhibit impaired cognition than non-
ADT patients and healthy controls [3]. A recent conflicting reports exists, though different 
tests were used than earlier reports [5]. Neurobehavioral symptoms (i.e., behavioral signs 
and symptoms of neurological impairment) that can underlie cognitive problems may also 
affect ADT patients [6].
Few nonpharmacologic approaches exist to treat cancer-related cognitive impairment. To the 
best of the authors’ knowledge, no known studies have focused specifically on treating 
cognitive dysfunction in ADT patients. Although a recent study in ADT patients showed that 
engaging in aerobic exercise was associated with better cognitive change scores than usual 
care [7], participants were not screened for cognitive impairment as it was not the primary 
outcome, and cognition was assessed with only two items from a quality of life 
questionnaire. In a recent Cochrane review of non-pharmacologic approaches to treat cancer-
related cognitive impairment [8], only five studies were eligible for inclusion, and all were in 
breast cancer. The studies focused on computerized cognitive training (CCT; involving 
repetitive practice of cognitive skills), compensatory strategy training (involving learning 
strategies to manage cognitive impairments), meditation, and exercise. Findings suggested 
that CCT and compensatory strategy training showed promise. A more recent study tested a 
15-week CCT program in a mixed group of non-central nervous system cancer survivors [9]. 
CCT led to improvements in self-reported cognitive symptoms compared with standard care, 
but not on neuropsychological outcomes.
Should the findings of the aforementioned studies translate to ADT patients [8, 9], then CCT 
could be a promising intervention for them, because it is easily disseminable and requires 
little clinical oversight [10]. BrainHQ (Posit Science) is one such program. It is informed by 
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brain plasticity research that suggests that behavioral experiences can change cortical 
representations. Such changes are said to underlie basic-level perceptual, cognitive and 
motor skill learning which, in turn, underlies higher-level cognitive and behavioral functions 
[10]. The foundational importance of basic-level skills is also supported by cognitive aging 
research [11]. BrainHQ trains basic-level functions in order to also support higher-level 
functions. In two breast cancer CCT trials – one that targeted speed of processing (using 
BrainHQ) and memory, and the other that targeted executive functioning – CCT led to 
domain-specific cognitive improvements that transferred to higher-level cognitive functions, 
symptom distress and quality of life in the former, and self-reported cognitive function in 
both studies [12, 13].
The purpose of the present study was to examine the feasibility, acceptability, and 
preliminary efficacy of home-based CCT (BrainHQ) to improve cognitive functioning in 
ADT patients with cognitive or neurobehavioral impairment. We hypothesized that 1) >50% 
of eligible participants would agree to be randomized and >70% would complete the study 
[14–16]; 2) CCT participants would be satisfied with and enjoy CCT; and 3) CCT would 
improve basic-level cognitive performance more than usual care (UC). Effects on secondary 
outcomes (i.e., higher-level cognitive performance, self-reported cognitive functioning, 
neurobehavioral functioning, and quality of life) were also explored.
METHODS
Study Design
This pilot study consisted of a two-group randomized controlled trial comparing CCT with 
UC in prostate cancer patients who had been on ADT for ≥3 months. Patients were screened 
and outcomes assessed at baseline, immediately after the 8-week intervention or equivalent 
time point (T2), and 8 weeks later (T3). The planned sample size for the study was 40 in the 
CCT group and 20 in the UC group which i) was based on an established rule of thumb for 
pilot trials of at least 12 per group [17]; ii) facilitated the estimation of a 25% drop-out rate 
to within a 95% confidence interval of ±11% approximately, accounting for the difference in 
sample sizes between groups; and iii) ensured that available study resources were not 
exceeded during the planned data collection time frame of 2 years.
Recruitment and Procedures
Study approval was obtained by Mount Sinai’s Program for the Protection of Human 
Subjects. ADT patients were recruited between November 2012 and June 2014 from the 
following: a) Mount Sinai Hospital, New York; and b) listservs and online advocacy groups. 
Patients were informed that we were evaluating a program to help with concentration, 
thinking, or memory problems reported by some people who had undergone ADT. Informed 
consent was obtained from all participants. All remaining aspects of the study were 
conducted by phone and internet.
Screening baseline assessment—Interviews established that participants 1) had 
completed primary prostate cancer treatment, 2) had received ADT for ≥3 months, 3) could 
speak and read English, and 4) had access to a telephone and computer with internet access; 
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but were excluded if screening indicated the following: 1) neurological history likely to 
impair cognition; 2) active psychosis, clinically significant depression, or substance abuse; 
3) visual, hearing, or physical impairment; or 4) other previous cancer, secondary tumor, or 
metastasis. Baseline assessment consisted of an interview to gather demographic and 
medical information, computerized neuropsychological assessment (i.e., CNS Vital Signs; 
[18]), and completion of questionnaires on PsychData.com. Participants were actively 
guided by research staff to ensure accurate comprehension of instructions. Participants were 
eligible if they had mild cognitive or neurobehavioral impairment indicated either by 1) a 
score of ≥1 SD below the normative mean on any CNS Vital Signs subtest, 2) a score of ≥8 
on the Patient Assessment of Own Functioning Inventory (i.e., ≥1 SD above mean 
endorsements from a non-clinical sample [19, 20]), or 3) a T-score ≥60 on any Frontal 
Systems Behavior Scale subscale [21]. Prior cognitive intervention studies in cancer 
survivors have generally relied on self-reported cognitive impairment as the primary 
inclusion criteria. However, due to the known discrepancy between self-reported and 
objective cognitive impairment, we included individuals who met criteria for either [22]. 
Eligible participants were randomized to CCT or UC in a 2-to-1 ratio ensuring sufficient 
collection of feasibility and acceptability data, while minimizing reduction in power. The 
approach of block randomization was used in order to ensure balance between groups in a 2-
to-1 ratio of sample sizes in each group throughout the study [23].
Intervention—Within 3 days of Baseline, CCT participants were instructed to use 
BrainHQ (www.brainhq.com), which consisted of five visual attention and information 
processing exercises. Adaptive Bayesian algorithms ensure that virtually any participant can 
perform them and is optimally challenged. Exercises follow a defined order optimizing 
fidelity to the intervention. The “dose” was 1 h/day, 5 days/week for 8 weeks [24]. 
Adherence was promoted through daily email reminders and weekly phone calls. UC 
participants were permitted to try CCT for 8 weeks at the end of their participation. 
Although random assignment was completed by someone unconnected with the study, 
research staff were not blinded to study condition in order to facilitate contact with 
participants. Potential biases were minimized through computerized administration of 
outcome measures.
T2 and T3 assessment—These assessments replicated baseline except CCT participants 
completed additional questionnaires assessing CCT’s helpfulness and acceptability. All 
participants were offered a stress management/relaxation CD to thank them for their 
participation.
Participants who withdrew from the study—Participants who chose to withdraw 
from the study were asked about their reasons for dropping out. Their feedback was 
important for evaluating the acceptability of the study protocol and program. Participants 
who could not be reached were sent a thank you letter.
Measures
Feasibility—The percentage of eligible participants who agreed to randomization, 
retention rates, and completion rates was calculated. Guided by previous research [14–16], a 
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priori thresholds for feasibility were as follows: percentage of eligible participants who 
agreed to be randomized >50% and percentage of participants who completed the study 
>70%. Measures of participation were based on time spent on CCT measured by BrainHQ’s 
tracking software. Participants were also asked to complete participation logs noting when 
they started and ended training each day. Since BrainHQ cannot track training pauses, or if 
non-participants use the program, the logs were used to edit the tracked times. Completers 
were operationalized as participants who trained for ≥10 h in total which, although low, 
ensured that a sufficient number of participants would complete the training, thus permitting 
an evaluation of preliminary efficacy as well. Furthermore, this approximated the dose found 
in other studies to be efficacious (i.e., between 8 and 10 h) [25–27]. CCT participants also 
reported their experiences in the participation logs and weekly phone calls.
Acceptability—The 8-item Client Satisfaction Questionnaire [28] measured satisfaction 
with CCT using a 4-point Likert scale from 1 to 4 where a higher total score indicated 
greater satisfaction. Cronbach’s α was .88. The 7-item interest/enjoyment subscale of the 
Intrinsic Motivation Inventory [29] measured enjoyment of CCT using a 3-point Likert scale 
(1= ‘Not at all true,’ 4= ‘Somewhat true,’ and 7= ‘Very true’); a higher total score indicated 
greater interest/enjoyment. Cronbach’s α was .94. Content analysis of participation log 
comments and clinical notes from phone calls was undertaken to characterize participant 
experiences with CCT.
Objective cognitive functioning—CNS Vital Signs [18], a 30-min computer-
administered neuropsychological assessment tool, consists of seven cognitive tests that 
assess basic-level functions (reaction time, simple attention, processing speed, and motor 
speed) and higher-level functions (verbal memory, visual memory, and cognitive flexibility). 
CNS Vital Signs is sensitive to mild cognitive dysfunction and has psychometric 
characteristics (i.e., concurrent and discriminant validity) similar to that of conventional 
neuropsychological tests, and the ability to generate multiple forms, thus minimizing 
practice effects [18]. Using CNS Vital Signs’ embedded validity indicators, invalid scores 
were excluded from analyses and extreme low outliers were truncated to 3 SDs below the 
mean to reduce skewness.
Self-reported cognitive functioning—The 33-item Patient Assessment of Own 
Functioning Inventory (PAOFI) measures patient perceptions regarding the “adequacy of 
their [cognitive] functioning in various everyday tasks and activities” using a Likert scale 
from 1 (Almost Always) to 6 (Almost Never) [20]. Likert ratings of 1–3 were scored ‘1’ 
indicating impairment, and ratings from 4–6 were scored ‘0’ indicating no impairment. A 
total impairment score was calculated by summing the impaired items. Cronbach’s α was .
91.
Neurobehavioral functioning—The 46-item Frontal Systems Behavior Scale (FrSBe 
[21]) measures neurobehavioral difficulties (i.e., apathy, disinhibition, and executive 
dysfunction) using a 5-point Likert scale. Each total score was converted to a T-score. A 
higher T-score indicated greater dysfunction. Cronbach’s α was .90.
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Quality of life—The 39-item Functional Assessment of Cancer Therapy–Prostate [30] 
measures quality of life using a 5-point Likert scale. Total scores range from 0 to 156 with a 
higher score indicating better quality of life. Cronbach’s α was .93.
Sociodemographic and medical information—This data was captured by self-report. 
The Self-Administered Comorbidity Questionnaire assessed the presence of 13 comorbid 
conditions and their impact on functioning (range 0–39) [31].
Data Analyses
Descriptive statistics were used to characterize sociodemographic, clinical, and 
neuropsychological variables and to calculate feasibility and acceptability outcomes. Group 
differences were analyzed with independent t-tests. Preliminary efficacy was assessed using 
repeated measures linear mixed models (LMMs) using V.9.4 of SAS procedure MIXED. A 
dummy-coded group variable (CCT vs. UC) was entered as the independent variable to test 
main effects and a time by group variable to test interaction effects for each outcome. Effect 
sizes for each significant model and individual effect sizes for baseline-T2 and baseline-T3 
were calculated. For these exploratory analyses, a significance level of p<.05 was used.
RESULTS
Participant characteristics
Table 1 summarizes participant characteristics. Participants were predominantly White, 
married, college educated, and had high incomes. Groups did not differ significantly on 
sociodemographic characteristics (i.e., age, race/ethnicity [White vs. other], marital status 
[married/marriage-like relationship vs. other], years of education, and annual household 
income [<$95,000 vs. ≥$95,000]), nor on medical characteristics (i.e., medical 
comorbidities, primary treatment [surgery vs. other], time since diagnosis, and duration of 
ADT). Groups did not differ in cognitive functions (i.e., CNS Vital Signs cognitive domain 
scores, and PAOFI self-reported cognitive impairment) nor in neurobehavioral functions 
(i.e., FrSBe total T-score), except processing speed where the standard score for CCT 
(M=104.76, SD=19.11) was higher than that for UC (M=95.74, SD=9.97; t(50.86)=−2.26, 
p=.03) where equal variances were not assumed.
Feasibility
Enrollment and participation are illustrated in Figure 1. There were 174 patients approached 
– 156 through community recruitment and 18 at Mount Sinai. Eighty-seven were consented 
and screened (50% enrollment rate). Primary refusal reasons were lack of interest or lack of 
time. Seventy-three completed baseline, and 60 met randomization criteria. Retention was 
77.5% for CCT and 100% for UC at T2, and 72.5% for CCT and 100% for UC at T3. When 
we examined “completers” only, i.e., participants who trained ≥10 total hours in total, 
retention at T2 dropped to 65% and at T3 to 60%. Multiple reasons were reported for 
dropping out of CCT including the following: the program was not enjoyable, not helpful, 
time consuming, frustrating/highlighted problems with cognition, or unable to use the 
mouse. Completers trained on average 30.25 h (SD=8.35; range 14.55–46.05).
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Overall, feasibility thresholds were partially met (i.e., >50% randomization rate, but <70% 
completed the study). However, when all CCT participants were included, whether or not 
they were “completers,” it was deemed to be feasible (>70% retention).
Acceptability
Thirty-one CCT participants completed T2. Participants were mostly satisfied with CCT 
(mean=2.96, SD=.53) and found the program somewhat enjoyable (mean=4.40, SD=1.59). 
Content analysis of participation logs and clinical notes indicated that participants found 
CCT lengthy and challenging but were willing to keep training. Sixteen participants (52%) 
had difficulty finding time to train (“hard to get 1 hour in per day”) or had trouble 
completing the full hour. Other interfering factors included the following: tiredness (39%) 
(“I got sleepy in the middle of it”), health problems (35%) (“medical tests wore me out”), 
boredom (32%) (“boring after a while”), or being distracted (16%) (“after you’ve been at 
it… concentration goes down”). A majority mentioned that the exercises were challenging 
(68%) (“hard time especially with the birds”). Other obstacles included technical problems 
(58%) such as the computer freezing, and a few noted side effects such as hand pain or eye 
strain (19%).
Participants were motivated to address barriers by taking breaks (39%) (“30 minute chunks 
helped me to sustain concentrating”) or training during optimal times (29%) (“did better at 
night”). A majority of participants (77%) reported that training was “going fine, ok, or well,” 
some noting that they felt stimulated (16%) (“they are interesting tests for my brain”) or 
enjoyed CCT (13%) (“I am enjoying doing the training”). Some noticed general 
improvement (23%) (“I think I’ve made progress”) or improvement on specific skills (“my 
range of vision is increasing”). Hence, despite obstacles to participation, most participants 
completed the minimally acceptable amount of training.
Preliminary efficacy
Primary outcomes—In all repeated measures LMMs, years of education was entered as a 
covariate because it is often associated with cognition [32] and was significantly associated 
with two of the 4 primary outcomes (i.e., reaction time and processing speed). Table 2 
contains between-within effect sizes based on least squares means for all outcomes for 
baseline-T2 and baseline-T3.
Among study completers, the LMM analysis showed that years of education was positively 
associated with reaction time performance. A significant time effect (F[2,83]=9.15; p=<.
001) indicated that reaction time improved over time. A significant time by group effect 
(F[2,83]=5.22; p=.007) indicated that groups differed with respect to change in reaction time 
over time. The CCT group’s reaction time improved significantly from baseline to T2 then 
remained stable to T3, while the UC group’s reaction time remained stable over time (see 
Figure 2). There was a medium effect size for the model (d=.70) [33] indicating that reaction 
time improved more in the CCT group over time than in the UC group. No other statistically 
significant interaction effects were found among study completers on the other primary 
outcome variables (i.e., simple attention, processing speed, motor speed).
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Among the intent-to-treat group, LMM results followed the same patterns as for study 
completers indicating a significant time effect (F[2,93]=6.22; p=.003) and a significant time 
by group effect (F[2,93]=3.18; p=.046) for reaction time with a medium effect size (d=.50). 
No other statistically significant interaction effects were found among intent-to-treat 
participants on the other primary outcome variables.
Secondary outcomes—Among study completers, the LMM for verbal memory indicated 
a significant time by group effect (F[2,86]=4.32; p=.02). UC’s verbal memory improved 
compared with the CCT group’s from baseline to T2, but by T3, verbal memory in the UC 
group had declined so that there was no longer a favorable effect from being in the UC 
group compared with the CCT group. There was a medium effect size for the overall model 
(d=.63). The LMM for visual memory indicated a significant time by group effect 
(F[2,86]=3.61; p=.03). The CCT group’s visual memory declined from baseline to T2 
compared with UC, but returned to baseline levels by T3. There was a medium effect size 
for the overall model (d=.59). No other statistically significant interaction effects were found 
among study completers on the other secondary outcome variables (i.e., cognitive flexibility, 
self-reported cognitive functioning, neurobehavioral functioning, or quality of life).
Among the intent-to-treat group, LMMs indicated a significant time by group effect 
(F[2,96]=5.04; p=.008) for verbal memory with a medium effect size (d=.67). No other 
statistically significant interaction effects were found among intent-to-treat participants on 
the remaining secondary outcome variables.
DISCUSSION
This is the first study to examine CCT in ADT patients. Preliminary efficacy was 
demonstrated for reaction time, but not other cognitive functions. Many BrainHQ tasks 
require rapid responses to visual stimuli so it is not surprising that reaction time improved. 
However, there was an unexpected temporary suppression of two higher-level functions – 
verbal and visual memory – that was not sustained 8 weeks post-CCT. These results 
contradict findings that do show transfer from basic-level to higher-level abilities (including 
memory) following CCT [12, 34]. It is possible that improvements in reaction time may be 
insufficient for transfer to higher-level functions and that improvements in other basic 
functions, such as processing speed, may be necessary for such a transfer to occur [11]. 
Furthermore, a study by van der Linden and colleagues [35] provides another possible 
explanation for these results. When cognitive fatigue was induced in healthy participants 
using a 2-h cognitively demanding task, fatigued participants performed worse on higher 
level (executive functioning) tasks than controls, but basic attention was unaffected. 
Consistent with this work, neuroimaging studies indicate that there are significant 
associations between mental fatigue and brain activity during more complex and fatiguing 
cognitive tasks, but not during less demanding cognitive tasks [36]. Given that the trainees in 
the current study trained on average 2 h per week more than what has been prescribed in 
other studies focused on visual speed of processing training (when averaged by number of 
weeks of training), this explanation seems possible. In other words, our trainees may have 
experienced cognitive fatigue associated with computer use that suppressed memory 
performance temporarily, but recovered after 8 weeks of rest, leaving reaction time 
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improvements intact. It is also possible that repetitive practice on the largely visual-motor 
and reaction time tasks were rehearsed more than, or even interfered with, verbal and visual 
learning processes. There was no effect of CCT on self-reported cognitive functioning, 
neurobehavioral functioning, nor quality of life suggesting that its potential may be limited 
to a narrow area of functioning, at least in the short-term.
Results provide tentative support for CCT’s feasibility and acceptability. The 50% 
enrollment rate reflects a common challenge in this population, possibly relating to gender. 
A psychosocial intervention study that examined accrual challenges in prostate cancer 
patients and their spouses found that refusals were greater among the male patients than 
their female spouses [37]. However, our enrollment was higher than that of a technology-
assisted psychosocial intervention study for prostate cancer patients [38] possibly because 
our participants could train in their own time, or maybe our study’s focus felt less 
threatening.
Retention rates were good (>70%), but lower when participants who completed less than 10 
h of training were excluded (≥60%). Numerous reasons were cited for terminating CCT such 
as finding it unenjoyable or time consuming. Shorter training times, as in other studies [12, 
13], may have been more palatable for these participants. Participants who did complete the 
minimally acceptable amount of training trained for 75% of the prescribed duration (i.e., 
~45 min/weekday).
Most CCT studies in cancer patients have focused on efficacy [12, 13]. Although our CCT 
participants were mostly satisfied with the program, challenges to CCT uptake can reduce its 
utility if not addressed. About 40% of participants found CCT lengthy or difficult to fit into 
their schedule. One third found it boring or had trouble staying focused, often due to health 
problems or tiredness. Two-thirds found the exercises challenging. Sixty percent experienced 
technical problems. A few noted side effects such as hand pain or eye strain. Despite these 
challenges, participants were generally motivated to overcome them using various strategies. 
The most popular strategy (40%) was to take breaks or break up training into chunks. 
Almost a third indicated that training during alert times of the day was helpful. Based on this 
data, certain elements are necessary to optimize CCT’s utility: 1) basic computer skills are a 
necessity; 2) patients should be told that training may be more challenging to stick to than 
expected, and given strategies, such as breaking up training into chunks, to optimize 
adherence; and 3) detailed technical guidance should be provided at the beginning of 
training.
Findings need to be understood in the context of some limitations. First, our sample was 
predominantly white, married, college educated, with high incomes, and diagnosed 
relatively young (mean age at diagnosis was 59), thus limiting its generalizability. Second, 
because CCT was compared to UC rather than an attention control condition, improvements 
(and declines) may have been due to nonspecific effects. An attention control condition 
involving participation in nonadaptive computer activities may have been a more appropriate 
or important additional condition, especially since computer use may be cognitively 
fatiguing. Third, although BrainHQ targets visual attention and processing skills that may 
contribute to the visuomotor skills most vulnerable to impairment in ADT patients, it does 
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not train them directly. Fourth, our ability to detect effects was likely limited by the small 
sample size and the mild severity of participants’ cognitive impairment.
In conclusion, this study provides information about the feasibility, acceptability and 
preliminary efficacy of CCT to treat cognitive impairment in ADT patients. We have 
demonstrated that BrainHQ [4] may be a promising tool for patients with cognitive 
difficulties that affect reaction time, but transfer to higher level abilities found in other 
studies did not occur [34]. Future studies are necessary to determine whether these results 
hold in a larger sample, to determine whether a shorter prescribed dose may be more 
efficacious for improving cognitive functions, and to clarify whether cognitive fatigue was 
responsible for the unexpected memory findings. Given that few approaches to treat cancer-
related cognitive impairment have been tested adequately and even fewer in ADT patients 
[8], the development and assessment of tools to treat cognitive impairment in ADT patients 
becomes all the more important.
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Fig. 1. 
Consort diagram
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Fig. 2. 
Least squares means and standard error bars for outcomes with significant interaction effects 
– completer analyses.
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